The 36-month beta value for BNGO is also noteworthy at 2.33. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The average price estimated by analysts for BNGO is $5.10, which is $4.15 above than the current price. The public float for BNGO is 291.38M, and at present, short sellers hold a 19.79% of that float. The average trading volume of BNGO on March 17, 2023 was 6.84M shares.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
BNGO) stock’s latest price update
Bionano Genomics Inc. (NASDAQ: BNGO)’s stock price has decreased by -4.17 compared to its previous closing price of 1.20. however, the company has experienced a -8.00% decrease in its stock price over the last five trading days. The Wall Street Journal reported on 10/12/21 that Airbnb, Merck, High Tide, Square: What to Watch in the Stock Market Today
BNGO’s Market Performance
BNGO’s stock has fallen by -8.00% in the past week, with a monthly drop of -26.75% and a quarterly drop of -43.07%. The volatility ratio for the week is 8.59% while the volatility levels for the last 30 days are 7.00% for Bionano Genomics Inc. The simple moving average for the last 20 days is -14.47% for BNGO stock, with a simple moving average of -40.57% for the last 200 days.
Analysts’ Opinion of BNGO
Many brokerage firms have already submitted their reports for BNGO stocks, with Scotiabank repeating the rating for BNGO by listing it as a “Sector Outperform.” The predicted price for BNGO in the upcoming period, according to Scotiabank is $4 based on the research report published on January 05th of the current year 2023.
BTIG Research, on the other hand, stated in their research note that they expect to see BNGO reach a price target of $3.50. The rating they have provided for BNGO stocks is “Buy” according to the report published on December 12th, 2022.
Oppenheimer gave a rating of “Outperform” to BNGO, setting the target price at $12 in the report published on July 18th of the previous year.
BNGO Trading at -26.85% from the 50-Day Moving Average
After a stumble in the market that brought BNGO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.56% of loss for the given period.
Volatility was left at 7.00%, however, over the last 30 days, the volatility rate increased by 8.59%, as shares sank -29.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.14% lower at present.
During the last 5 trading sessions, BNGO fell by -8.00%, which changed the moving average for the period of 200-days by -34.29% in comparison to the 20-day moving average, which settled at $1.3205. In addition, Bionano Genomics Inc. saw -21.23% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BNGO starting from Linney Yvonne, who sale 20,000 shares at the price of $3.62 back on Aug 15. After this action, Linney Yvonne now owns 0 shares of Bionano Genomics Inc., valued at $72,402 using the latest closing price.
BARKER DAVID L, the Director of Bionano Genomics Inc., purchase 10,000 shares at $1.60 during a trade that took place back on May 16, which means that BARKER DAVID L is holding 13,894 shares at $16,000 based on the most recent closing price.
Stock Fundamentals for BNGO
Current profitability levels for the company are sitting at:
- -466.09 for the present operating margin
- -9.55 for the gross margin
The net margin for Bionano Genomics Inc. stands at -476.93.
The liquidity ratio also appears to be rather interesting for investors as it stands at 4.38.
Conclusion
In summary, Bionano Genomics Inc. (BNGO) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
